Meningitis Due to Haemophilus Influenzae Type

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

EMA approval · 2026-07-10
EMA Authorised: Infanrix Hexa (Diphtheria toxoid;tetanus toxoid;Bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin);hepatitis B surface antigen;poliovirus (inactivated) (type-1 (Mahoney strain), type-2 (MEF-1 strain), type-3 (Saukett strain));Haemophilus influenzae type b polysaccharide) — GlaxoSmithKline Biologicals S.A.
EMA has authorised Infanrix Hexa, a hexavalent vaccine by GlaxoSmithKline Biologicals S.A., covering multiple antigens including diphtheria,…
EMA approval · 2026-03-31
EMA Authorised: Vaxelis (Diphtheria toxoid;tetanus toxoid;Bordetella pertussis antigens: pertussis toxoid, filamentous haemagglutinin, pertactin, fimbriae Types 2 and 3;hepatitis B surface antigen produced in yeast cells;poliovirus (inactivated): type 1 (Mahoney), type 2 (MEF-1), type 3 (Saukett) produced in Vero cells/ Haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) conjugated to meningococcal protein.) — MCM Vaccine B.V.
The EMA has authorised Vaxelis, a combination vaccine containing diphtheria and tetanus toxoids, pertussis antigens, hepatitis B surface ant…
CLINICAL_TRIALS trial_result · 2012-04-19
Clinical Trial Update: Immunogenicity and Safety of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine in Infants and Children [Phase 3]
Phase 3 trial assessing immunogenicity and safety of a combined Group A, C meningococcal and Haemophilus influenzae type b conjugate vaccine…